National Health Investors (NHI) recently reported fourth quarter and full year 2025 results, with higher sales and revenue and softer quarterly earnings, a combination that provides a detailed snapshot of current margin pressures.

The mixed fourth quarter earnings and board changes arrived after a period of steadily improving performance, with the latest share price at $84.62, a 90 day share price return of 7.98% and a 1 year total shareholder return of 19.8% suggesting momentum has been building over both shorter and longer horizons.

If you are reassessing your income and growth ideas after NHI’s update, it could be worth scanning our list of 19 top founder-led companies as potential next candidates for your watchlist.

With revenue and net income trends moving in different directions, a recent 1 year total return of 19.8%, and the share price sitting near the US$88.38 analyst target, it is worth asking whether there is still a buying opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 1.2% Undervalued

The widely followed narrative pegs National Health Investors’ fair value at $85.63, just above the recent $84.62 share price, which keeps the valuation debate finely balanced.

NHI's focused expansion of its SHOP (Senior Housing Operating Portfolio) segment, with double-digit NOI growth projected and a robust pipeline of accretive acquisitions, positions the company for outsized multi-year NOI and earnings growth relative to peers.

Curious what earnings path and margin profile would need to unfold for that fair value to hold up? The narrative leans on steady cash flows, rising revenue and a future earnings multiple that assumes investors will keep paying up for consistency.

Result: Fair Value of $85.63 (UNDERVALUED)

However, there are pressure points to watch, including tenant concentration in operators like Discovery and Bickford, as well as reliance on new share issuance that could dilute future per share outcomes.

Another Take On The Valuation

While the fair value narrative sits close to the current $84.62 price, the P/E story pulls in a different direction. NHI trades on a 28.8x P/E, above the 25.9x Health Care REITs average but below its own 37.9x fair ratio. This points to both upside potential and re rating risk if sentiment cools.

To see what the numbers say about this price, and how that gap to the fair ratio could close over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given this mix of positives and pressure points, it makes sense to look at the full data yourself and move quickly to form your own view, starting with 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If NHI’s story has sharpened your thinking, do not stop here. Widen your search with a few focused stock ideas built from our screeners.

• Target reliable income by reviewing our hand picked group of 16 dividend fortresses that could suit investors who want yield front and center.
• Zero in on pricing power by checking a curated set of 50 high quality undervalued stocks that combine quality fundamentals with what our models flag as appealing entry points.
• Prioritize resilience by scanning a focused selection of 66 resilient stocks with low risk scores designed for investors who want to keep potential downside firmly in check.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.